Tevogen Bio Holdings shareholders approved an amendment to the company’s 2024 equity incentive plan and authorized a flexible reverse stock split at a ratio between 1-for-25 and 1-for-85, to be implemented at the board’s discretion. Both proposals received strong support, aimed at adjusting the capital structure and equity incentives. TipRanks’ AI Analyst, Spark, rates TVGN as Neutral due to very weak financial performance and a strong downtrend in technicals.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Tevogen Bio Shareholders Approve Reverse Split Authorization
Tevogen Bio Holdings shareholders approved an amendment to the company’s 2024 equity incentive plan and authorized a flexible reverse stock split at a ratio between 1-for-25 and 1-for-85, to be implemented at the board’s discretion. Both proposals received strong support, aimed at adjusting the capital structure and equity incentives. TipRanks’ AI Analyst, Spark, rates TVGN as Neutral due to very weak financial performance and a strong downtrend in technicals.